These COVID-19 clinical trials are active and approved by Health Canada. Many more are pending approval and will be added in the days and weeks ahead.
Help us complete the circle. Add your trial to our list of active COVID-19 Canadian clinical trials and gain access to a wider participant registry.
This study is for people who are hospitalized with COVID-19 who are at high risk for complications. Study participants will receive either (1) LAU-7b with standard of care, or (2) placebo with standard of care. The study is to see if LAU-7b prevents severe COVID-19 symptoms and death.
This study is for people who are hospitalized for COVID-19. All study participants will get convalescent plasma (a part of blood) to see if it prevents death and reduces intubation, and to see whether people are able to leave the intensive care unit and the hospital faster.
This study compares tocilizumab with placebo in people who are hospitalized with severe COVID-19 to see if tocilizumab improves clinical symptoms.
This study is for people who are hospitalized with severe or critical COVID-19 infection. The study compares sarilumab and placebo to see if sarilumab prevents death and impoves clinical symptoms of COVID-19.
This study is for people who have COVID-19, who are not admitted in the hospital, and who meet study-related high-risk criteria. The study compares colchicine to placebo to see if colchicine prevents hospitalization or death.
This study is for children hospitalized with COVID-19. Study participants will know which therapy they receive, and it will be either (1) standard of care, or (2) convalescent plasma and standard of care. The study is to see if convalescent plasma improves clinical symptoms of COVID-19 and to see if it prevents death.
This study is for patients who are hospitalized in the intensive care unit for COVID-19. The study compares high-dose Vitamin C with placebo to see if Vitamin C prevents sepsis, and therefore prevents death or persistent organ dysfunction.
This study is for people who work or live with patients who have COVID-19, or who work in places that have high risk of contact with patients who have COVID-19. Study participants will either (1) take standard precautions, or (2) take standard precautions and Nitric Oxide Releasing Solution (NORS) to see if NORS prevents COVID-19 infection. Study participants who become COVID-19 positive will take NORS to see if it reduces hospitalization, oxygen therapy, or the need for machines to help with breathing.
This study tests whether hydroxychloroquine can (1) prevent COVID-19 after someone has been exposed to SARS-CoV-2 coronavirus, and (2) prevent hospitalizations and severe symptoms in people who have tested positive for COVID-19. People in the study with take hydroxychloroquine or a placebo.
This study is for people who are hospitalized in the intensive care unit for COVID-19. The study measures whether different treatments and combinations of treatments will prevent death.
This study is for people who are hospitalized for COVID-19. Study participants will receive heparin or usual care, to see if heparin prevents the need for a machine to help with breathing or death.
This study is for people who are admitted in the hospital with COVID-19. The study compares 4 different treatments to prevent death and improve clinical symptoms. The study participants will know which treatment they are getting, which will be one of: (1) standard care, (2) lopinavir/ritonavir with standard care, (3) hydroxychloroquine with standard care, or (4) remdesivir with standard care.